Stelara 45 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F3GC1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $69,844
Award facts
- Contract value 100% obligated
- $69,844.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $69,844.26, was awarded to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) on January 30, 2026, by the Defense Logistics Agency for the supply of STELARA 45 mg/0.5 ml syringes. The award is a firm fixed-price delivery order with an ultimate completion date of February 2, 2026, and will be performed at the awardee's location in Conshohocken, Pennsylvania. This contract was not set aside and was competitively awarded, reflecting the company's capability to meet federal procurement requirements through open competition. The award is issued under Amerisourcebergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
Amerisourcebergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement support to the Defense Logistics Agency's Medical Supply Chain, with an extensive portfolio covering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The Defense Logistics Agency's pharmaceutical procurement through such prime vendor contracts ensures reliable access to essential medications for military treatment facilities and veterans' healthcare programs. STELARA is an immunosuppressant biologic used to treat various autoimmune conditions including psoriasis, psoriatic arthritis, and inflammatory bowel disease, making this delivery order part of the agency's broader effort to maintain adequate pharmaceutical inventory for military healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F3GC1?
SPE2DR26F3GC1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26F3GC1 worth?
The government has obligated $69,844 on SPE2DR26F3GC1.
Is contract SPE2DR26F3GC1 an order under another contract?
Yes. SPE2DR26F3GC1 is a delivery order under SPE2DR25D3017, an indefinite delivery contract.
Was contract SPE2DR26F3GC1 competed?
The extent of competition for SPE2DR26F3GC1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award